Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia

• Status: Completed
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in the treatment of young women with schizophrenia and schizoaffective disorder. Raloxifene is a Selective Estrogen Receptor Modulator (SERM),which means that it can affect the central nervous system (CNS) effects of estrogen (eg. improving emotional symptoms, memory, information processing and concentration), without adversely affecting reproductive tissue/organs such as breast, uterus and ovaries. The investigators are conducting a double-blind, placebo controlled, three month study comparing the psychotic symptom response of women with schizophrenia in both groups. One group will receive standard antipsychotic medication plus 120mg Raloxifene, while the second group will receive standard antipsychotic medication plus oral placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Alfred
• Collaborator: Monash University
• Treatments: Estrogen Receptor Modulators; Estrogens; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators

Criteria

Inclusion Criteria:

• Physically well

• A current DSM-IV diagnosis of schizophrenia or related disorder.

• 18- 45 years

• Premenopausal (regular menstrual cycles and follicle stimulating hormone < 40 mIU/ml; for hysterectomised women, FSH< 40mIU/ml and estradiol> 120pmol/L)

• Able to give informed consent.

• PANSS total score > 60 (1 - 7 scale) and a score of 4 (moderate) or more on two or more of the following PANSS items: delusions, hallucinatory behaviour, conceptual disorganization or suspiciousness.

• No abnormality observed during physical breast examination.

• Documented normal PAP smear and pelvic examination in the preceding two years.

Exclusion Criteria:

• Patients with known abnormalities in the hypothalamo-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, or undiagnosed vaginal bleeding.

• Patients with any significant unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; presence of illness causing immobilisation.

• Patients whose psychotic illness is directly related to illicit substance use or who have a history of substance abuse or dependence during the last six months, or consumption of more than 30gm of alcohol (three standard drinks) per day.

• Smoking more than 20 cigarettes per day.

• Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including tibolone or use of phytoestrogen supplements as powder or tablet.